Glazer Funds Report 0 Shares of Amicus Common Stock
Amicus Therapeutics, Inc. received a Schedule 13G filing from Glazer Capital, LLC and Paul J. Glazer identifying themselves as former large holders.
Rhea-AI Filing Summary
Amicus Therapeutics, Inc. received a Schedule 13G filing from Glazer Capital, LLC and Paul J. Glazer identifying themselves as former large holders. The filing states the Reporting Persons currently beneficially own 0 shares of Amicus common stock (CUSIP 03152W109) representing 0% of the class.
The statement notes the Reporting Persons "have ceased to be the beneficial owner of more than five percent of the class of securities." The filing lists the Reporting Persons' business address and is signed by Paul J. Glazer on 05/01/2026.
Positive
- None.
Negative
- None.
Insights
Glazer Funds now report no beneficial ownership in Amicus common stock.
The Schedule 13G shows 0 shares and 0% ownership for Glazer Capital and Paul J. Glazer, dated filings around 04/24/2026 with signatures on 05/01/2026. This indicates they no longer hold a >5% position reported earlier.
For investors, the item is administrative: subsequent filings or trading reports would reveal whether disposition was gradual or a single transaction. Future public filings may disclose details of any prior >5% position change.
Key Figures
Key Terms
Schedule 13G regulatory
beneficial owner regulatory
Section 13 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Glazer Capital report for Amicus Therapeutics (FOLD)?
Does the Schedule 13G show Glazer still holds >5% of FOLD?
Who filed the Schedule 13G for Amicus and where is their address?
What date(s) are shown on the Amicus Schedule 13G filing?
What class and CUSIP does the filing reference for Amicus?
AI-generated analysis. How Rhea-AI works. Not financial advice.